Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 167 clinical trials
Stem Cell Transplant in Patients With Severe Sickle Cell Disease

-myeloablative conditioning regimen (Alemtuzumab).

chest syndrome
iron overload
acute chest syndrome
iron
alemtuzumab
  • 30 views
  • 02 Apr, 2021
  • 1 location
Ruxolitinib and Decitabine for High Risk Hematological Malignancies

The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Decitabine intensified Conditioning Regimen in Patients with High Risk hematological malignancies undergoing

  • 0 views
  • 25 Jan, 2021
  • 1 location
Clofarabine Pre-allogeneic Stem Cell Transplant for Non-remission AML

The Investigators would like to study the incidence of complete remission (CR) at day +30 after Clofarabine followed by haploidentical transplant. The conditioning regimen used is Fludarabine

tacrolimus
remission
filgrastim
clofarabine
transplant conditioning
  • 0 views
  • 27 Jan, 2021
  • 1 location
Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)

transplant with either a myeloablative or non-myeloablative conditioning regimen, and recipients of all donor sources will be enrolled to this trial.

  • 0 views
  • 24 May, 2021
  • 1 location
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission

antagonist, as a chemo sensitization strategy, plus chemotherapy as the conditioning regimen for autologous or allogeneic hematopoietic stem cell transplantation (HSCT).

remission
lymphoid leukemia
transplant conditioning
ejection fraction
myeloid leukemia
  • 17 views
  • 24 Jan, 2021
  • 1 location
Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia

cell transplantation (allo-HSCT) adding gemcitabine to the standard institutional conditioning regimen based on two alkylating drugs, reduced busulfan and cyclophosphamide (reduced BUCY 2).

  • 1 views
  • 24 Jan, 2021
  • 1 location
Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases

The hypothesis of this study is that children with severe primary immunodeficiencies will benefit from early stem cell transplantation utilizing a reduced intensity conditioning regimen

  • 8 views
  • 07 Nov, 2020
  • 1 location
Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies

This is a Phase II trial to determine the ability of a reduced intensity conditioning regimen to allow successful engraftment with alpha/beta T and CD19+ depleted peripheral stem cell grafts

severe combined immunodeficiency
reduced intensity conditioning
histiocytosis
transplant conditioning
shortening fraction
  • 3 views
  • 24 Jan, 2021
  • 1 location
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

The purpose of this study is to evaluate the safety of reducing and ultimately eliminating anti-thymocyte globulin (ATG) from the haplo-cord transplant conditioning regimen and replacing it with

lymphoma
myeloproliferative disorder
lymphoid leukemia
chronic lymphocytic leukemia, relapsed
remission
  • 0 views
  • 26 Jan, 2021
  • 1 location
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with

sickle hemoglobin
hb s
alemtuzumab
splenic sequestration crisis
conditioning regimen
  • 9 views
  • 03 Jun, 2021
  • 1 location